Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy
Public ClinicalTrials.gov record NCT03616834. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Phase 2, open-label study that will evaluate the safety, tolerability, antitumor activities.
Study identification
- NCT ID
- NCT03616834
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 39 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 24, 2018
- Primary completion
- Jan 30, 2021
- Completion
- Jun 29, 2021
- Last update posted
- Mar 21, 2023
2018 – 2021
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona - Cancer Center | Tucson | Arizona | 85724 | — |
| Pacific Shores Medical Group | Long Beach | California | 90813 | — |
| Hoag Memorial Hospital Presbyterian | Los Angeles | California | 90033 | — |
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| St. Mary's Medical Center | San Francisco | California | 94117 | — |
| St. Joseph Heritage Healthcare | Santa Rosa | California | 95403 | — |
| Columbus Regional Research Institute | Columbus | Georgia | 31904 | — |
| Saint Alphonsus Regional Medical Center | Boise | Idaho | 83706 | — |
| Indiana University Health Melvin & Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| Anne Arundel Medical Center | Annapolis | Maryland | 21401 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Universty of Toledo Medical Center | Toledo | Ohio | 43614 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Spartanburg Medical Center | Spartanburg | South Carolina | 29303 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | — |
| Oncology Consultants | Houston | Texas | 77024 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
| University of Wisconsin Clinical Science Center | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03616834, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 21, 2023 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03616834 live on ClinicalTrials.gov.